In the BioHarmony Drug Report Database

"Preview" Icon

Triazolam

Halcion (triazolam) is a small molecule pharmaceutical. Triazolam was first approved as Halcion on 1982-11-15. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-1, and gamma-aminobutyric acid receptor subunit alpha-5.

 

Trade Name

 

Halcion
 

Common Name

 

triazolam
 

ChEMBL ID

 

CHEMBL646
 

Indication

 

sleep initiation and maintenance disorders
 

Drug Class

 

Image (chem structure or protein)

Triazolam structure rendering